PellePharm Overview
- Year Founded
-
2012
- Status
-
Private
- Employees
-
8
- Latest Deal Type
-
2ndary - Private
- Investors
-
6
PellePharm General Information
Description
Developer of skin cancer therapeutics intended to mitigate the tumor burden of basal cell carcinomas. The company's therapeutics include a topical hedgehog inhibitor, which decreases the number of surgically-eligible basal cell carcinomas in Gorlin syndrome patients, enabling healthcare providers to treat cancer by potentially reducing invasive and painful surgeries.
Contact Information
Website
www.pellepharm.comCorporate Office
- 3160 Porter Drive
- Suite 250
- Palo Alto, CA 94304
- United States
Corporate Office
- 3160 Porter Drive
- Suite 250
- Palo Alto, CA 94304
- United States
PellePharm Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 7. Secondary Transaction - Private | 01-Apr-2023 | Completed | Generating Revenue | |||
| 6. Later Stage VC | 20-Nov-2018 | Completed | Generating Revenue | |||
| 5. Later Stage VC (Series C) | 18-Jun-2018 | Completed | Generating Revenue | |||
| 4. Debt - General | 29-Mar-2018 | Completed | Generating Revenue | |||
| 3. Later Stage VC (Series B2) | 31-Jul-2017 | Completed | Generating Revenue | |||
| 2. Early Stage VC (Series B) | 23-Jul-2015 | $4.55M | $7.67M | Completed | Generating Revenue | |
| 1. Early Stage VC (Series A) | 11-May-2015 | $3.12M | $3.12M | Completed | Generating Revenue |
PellePharm Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series C | ||||||||
| Series B2 | ||||||||
| Series B | 3,888,889 | $0.000100 | $0.09 | $1.17 | $1.17 | 1x | $1.17 | 8.67% |
| Series A | 3,712,649 | $0.000100 | $0.84 | $0.84 | 1x | $0.84 | 8.27% |
PellePharm Comparisons
Industry
Financing
Details
PellePharm Competitors (28)
One of PellePharm’s 28 competitors is Azitra, a Formerly VC-backed company based in Branford, CT.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Azitra | Formerly VC-backed | Branford, CT | ||||
| Xalud Therapeutics | Venture Capital-Backed | New York, NY | ||||
| Vera Therapeutics | Formerly VC-backed | Brisbane, CA | ||||
| Bolden Therapeutics | Venture Capital-Backed | Providence, RI | ||||
| Vertex Pharmaceuticals | Formerly VC-backed | Boston, MA |
PellePharm Patents
PellePharm Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2017139497-A1 | Hedgehog inhibitor for use in relief of and treatment of pruritus or itching | Inactive | 11-Feb-2016 | ||
| US-20170231968-A1 | Method for relief of and treatment of pruritus | Inactive | 11-Feb-2016 | ||
| JP-6796638-B2 | Topical formulations and their use for the delivery of hedgehog inhibitory compounds | Active | 04-Jun-2015 | ||
| WO-2016196928-A1 | Topical formulations for delivery of hedgehog inhibitor compounds and use thereof | Inactive | 04-Jun-2015 | ||
| JP-2021014469-A | Topical formulations for delivery of hedgehog inhibitor compounds and uses thereof | Pending | 04-Jun-2015 | A61K31/496 |
PellePharm Signals
PellePharm Investors (6)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| LEO Pharma | PE-Backed Company | Minority | ||
| EcoR1 Capital | Venture Capital | Minority | ||
| Angel (individual) | Minority | |||
| BridgeBio Pharma | Corporation | Minority | ||
| Piedmont Trust Company | Limited Partner | Minority |
PellePharm Affiliates
Subsidiaries (1)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| PellePharm (Hedgehog Signaling Pathway Blocker in San Francisco) | San Francisco, CA |
PellePharm FAQs
-
When was PellePharm founded?
PellePharm was founded in 2012.
-
Where is PellePharm headquartered?
PellePharm is headquartered in Palo Alto, CA.
-
What is the size of PellePharm?
PellePharm has 8 total employees.
-
What industry is PellePharm in?
PellePharm’s primary industry is Drug Discovery.
-
Is PellePharm a private or public company?
PellePharm is a Private company.
-
What is PellePharm’s current revenue?
The current revenue for PellePharm is .
-
How much funding has PellePharm raised over time?
PellePharm has raised $113M.
-
Who are PellePharm’s investors?
LEO Pharma, EcoR1 Capital, , BridgeBio Pharma, and Piedmont Trust Company are 5 of 6 investors who have invested in PellePharm.
-
Who are PellePharm’s competitors?
Azitra, Xalud Therapeutics, Vera Therapeutics, Bolden Therapeutics, and Vertex Pharmaceuticals are some of the 28 competitors of PellePharm.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process